Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

NCT02964065 is registered in ClinicalTrials.gov with Changchun BCHT Biotechnology Co. as lead sponsor.

NCT NCT02964065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02964065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)
Lead sponsor
Changchun BCHT Biotechnology Co.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2016
Completion date
Not reported
Enrollment
9,000 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza